Sernova Corp.

TSX:SVA.TO

Biotechnology

Healthcare
$0.14 -5.88%

-$0.01 today

Market cap
$50.98M
Beta
0.66
P/E (TTM)
-4.7
EPS (TTM)
-$0.03
52W Low $0.12High $0.21

Volume 0.55M

Average 0.12M

SVA.TO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Sernova Corp.TSX: SVA.TO

Operating Expenses · Q2 FY2026 · quarter ended Apr 2026

Operating expenses declines year over year

Q2 FY2026 operating expenses of CA$2.3M fell 47.0% year over year, ahead of the -51.3% change in trailing-twelve-month operating expenses. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at -15.8% a year.

Context

  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -47.0% holds above the trailing-twelve-month pace of -51.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
CA$2.3M+8.7% QoQ
Last fiscal yearOct 2025
CA$14.78M-53.6% YoY
LTMApr 2026
CA$10.21M-51.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.0%——
1 year-53.6%——
3-year CAGR-15.8%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

CAD · from the income statement

Latest · FY2025
14.78M CAD
Year-over-year change
-53.6%
4-year CAGR
+20.8%

Operating Expenses vs competitors

How SVA.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -51.3% is the lowest of 2, against a peer median of +31.8%.
  • Over three fiscal years its annual growth of -15.8% compares with a peer median of +21.5%.
SVA.TO Competitors
Operating Expenses for SVA.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCT.TOBriaCell Therapeutics Corp.LTM Apr 2026$31.98M USD+31.8%+21.5%—
SVA.TOSernova Corp.LTM Apr 2026CA$10.21M CAD-51.3%-15.8%—
Peer median (excluding SVA.TO) —+31.8%+21.5%—

Competitors are the stored peer set for SVA.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue267.2K440K445.55K540.28K342.59K
Gross Profit(267.2K)(440K)(445.55K)(540.28K)(342.59K)
Gross Margin—————
Research & Development4.64M16.9M32.26M22.36M7.28M
Selling, General & Admin2.29M7.83M8.46M8.97M7.5M
Operating Expenses6.94M24.75M41.13M31.84M14.78M
Depreciation & Amortization267.2K440K308.49K410.53K342.59K
EBITDA(6.6M)(24.54M)(40.19M)(31.25M)(14.74M)
EBITDA Margin—————
Operating Income(6.87M)(24.18M)(41.13M)(31.84M)(15.12M)
Operating Margin—————
Interest Income70.55K577.29K1.5M388.39K25.63K
Interest Expense58.37K118K32.08K586.86K754.81K
Other Income / Expenses1.09M1.01M1.5M(347.04K)(711.01K)
Income Before Tax(6.97M)(24.42M)(39.63M)(32.19M)(15.84M)
Pre-Tax Margin—————
Income Tax Expense58.37K118K(629.02K)7K(92.19K)
Net Income(7.02M)(24.54M)(39M)(32.19M)(15.74M)
Net Margin—————
EPS (Basic)(0.03)(0.09)(0.13)(0.10)(0.05)
EPS (Diluted)(0.03)(0.09)(0.13)(0.10)(0.05)
Weighted Avg Shares245.52M273.59M303.33M306.96M328.29M
Weighted Avg Shares (Diluted)245.52M273.59M303.33M306.95M328.29M

Sernova Corp.

TSX:SVA.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.